Approaches to protozoan drug discovery: phenotypic screening.
Determining the activity of a compound and the potential impact on a diseased state is frequently undertaken using phenotypic or target-based approaches. Phenotypic screens have the advantage of the whole organism being exposed to the compound and thus all the targets and biological pathways associated with it. Cell penetration and access to targets in their "natural" environment are taken into account. Unless utilizing a genetically modified organism with an additional target associated indicator, elucidation of specific target(s) of active compounds is necessary. Target discovery is desirable to allow development of chemical entities based upon knowledge of the target structure. Phenotypic drug discovery has successfully identified new molecular entities for neglected protozoan disease research. In this perspective, the phenotypic approaches used to identify chemical entities for drug discovery and for use as tools against the parasites Plasmodium falciparum, Trypanosoma brucei brucei, and Trypanosoma cruzi will be outlined.
Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University , Nathan, Queensland, Australia.
Melissa L
ML
Sykes
Vicky M
VM
Avery
D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D015394:Molecular Structure; D058069:Neglected Diseases / Q000469:parasitology / Q000517:prevention & control; D010641:Phenotype; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics; D011528:Protozoan Infections / Q000469:parasitology / Q000517:prevention & control*; D014344:Trypanocidal Agents / Q000737:chemistry / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei / Q000187:drug effects* / Q000235:genetics; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000235:genetics
D014344:Trypanocidal Agents